Literature DB >> 15081404

Human E2F6 is alternatively spliced to generate multiple protein isoforms.

Zoulika Kherrouche1, Yvan De Launoit, Didier Monté.   

Abstract

E2F6 protein belongs to the family of the E2F transcription factors. Here, we showed that the human E2F6 gene contains nine exons distributed along 20.4kbp of genomic DNA on chromosome 2 leading to the transcription of six alternatively spliced E2F6 mRNAs that encode four different E2F6 proteins. Moreover, we identified an E2F6 pseudogene localized on chromosome 22 completely spliced and devoid of exons 2, 3, and 4, and part of exons 1 and 5. Definition of the transcriptional initiation site and sequence analysis show that the gene contains a TATA less, CAAT less, GC-rich promoter with multiple transcription start sites. Regulatory elements necessary for basal transcription reside within a 134bp fragment as determined by transient transfection experiments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081404     DOI: 10.1016/j.bbrc.2004.03.099

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  A comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members.

Authors:  Xiaoqin Xu; Mark Bieda; Victor X Jin; Alina Rabinovich; Mathew J Oberley; Roland Green; Peggy J Farnham
Journal:  Genome Res       Date:  2007-10-01       Impact factor: 9.043

2.  Alternative splicing generates a diacylglycerol kinase α transcript that acts as a dominant-negative modulator of superoxide production in localized aggressive periodontitis.

Authors:  Eraldo L Batista; Alpdogan I Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  J Periodontol       Date:  2013-10-30       Impact factor: 6.993

3.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Konstantinos Evangelou; Sophia Havaki; Athanassios Kotsinas
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1.

Authors:  Florence Gizard; Romain Robillard; Olivier Barbier; Brigitte Quatannens; Anne Faucompré; Françoise Révillion; Jean-Philippe Peyrat; Bart Staels; Dean W Hum
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

5.  PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.

Authors:  Florence Gizard; Carole Amant; Olivier Barbier; Stefano Bellosta; Romain Robillard; Frédéric Percevault; Henry Sevestre; Paul Krimpenfort; Alberto Corsini; Jacques Rochette; Corine Glineur; Jean-Charles Fruchart; Gérard Torpier; Bart Staels
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

6.  The NRF-1/alpha-PAL transcription factor regulates human E2F6 promoter activity.

Authors:  Zoulika Kherrouche; Yvan De Launoit; Didier Monte
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

7.  ASK-1 (apoptosis signal-regulating kinase 1) is a direct E2F target gene.

Authors:  Zoulika Kherrouche; Alexandre Blais; Elisabeth Ferreira; Yvan De Launoit; Didier Monté
Journal:  Biochem J       Date:  2006-06-15       Impact factor: 3.857

8.  Predictive analysis of long non-coding RNA expression profiles in diffuse large B-cell lymphoma.

Authors:  Danxia Zhu; Cheng Fang; Xiaodong Li; Yiting Geng; Ruiqi Li; Chen Wu; Jingting Jiang; Changping Wu
Journal:  Oncotarget       Date:  2017-04-04

9.  E2F6 is essential for cell viability in breast cancer cells during replication stress.

Authors:  Inam Jasim Lafta
Journal:  Turk J Biol       Date:  2019-10-14

10.  Novel Potential Therapeutic Target for E2F1 and Prognostic Factors of E2F1/2/3/5/7/8 in Human Gastric Cancer.

Authors:  Xuhong Liu; Chunhong Hu
Journal:  Mol Ther Methods Clin Dev       Date:  2020-07-31       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.